Riehen, Switzerland

Frederick Monsma


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Frederick Monsma in Antiepileptic Research

Introduction: Frederick Monsma is a notable inventor based in Riehen, Switzerland, recognized for his significant contributions to the field of neuroscience. With one patent to his name, Monsma has embarked on research aimed at improving therapeutic outcomes for patients suffering from psychiatric and neurological disorders.

Latest Patents: Monsma's patent, titled "Method of Identifying Compounds Having Antiepileptic Anticonvulsant or Anxiolytic Activities," describes a groundbreaking method for screening compounds. The process involves testing an LC132 receptor agonist in a screening assay specifically designed for psychiatric and/or neurological disorders. This innovative method facilitates the identification of compounds that could be beneficial in treating conditions such as epilepsy and anxiety, marking a significant advancement in therapeutic research.

Career Highlights: Currently affiliated with Hoffmann-La Roche Inc., one of the leading pharmaceutical companies, Monsma has positioned himself at the forefront of drug discovery and innovation. His work primarily focuses on understanding the interactions between novel compounds and LC132 receptors, which are integral to developing effective treatments for neurological disorders.

Collaborations: Throughout his career, Monsma has collaborated with esteemed colleagues, including Olivier Civelli and James Richard Martin. These partnerships underscore the importance of teamwork in driving scientific discovery and innovation in the pharmaceutical industry.

Conclusion: Frederick Monsma's contributions to neuroscience and pharmacology, particularly through his patent on LC132 receptor agonists, demonstrate his commitment to advancing the understanding and treatment of mental health and neurological disorders. His ongoing work with Hoffmann-La Roche Inc. continues to play a pivotal role in the development of therapeutic innovations, reflecting the importance of research and collaboration in the field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…